Andrew Berens
Stock Analyst at Leerink Partners
(2.36)
# 2,564
Out of 5,152 analysts
99
Total ratings
48.19%
Success rate
-1.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Maintains: Outperform | $52 → $58 | $24.80 | +133.87% | 11 | Mar 3, 2026 | |
| COGT Cogent Biosciences | Maintains: Outperform | $14 → $15 | $37.46 | -59.96% | 6 | Jun 13, 2022 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $8 | $4.43 | +80.59% | 1 | Jan 23, 2026 | |
| GLTO Galecto | Initiates: Outperform | $46 | $28.36 | +62.20% | 1 | Jan 7, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $34 → $40 | $27.68 | +44.51% | 13 | Dec 26, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $140 → $149 | $100.13 | +48.81% | 3 | Nov 17, 2025 | |
| IMRX Immuneering | Initiates: Outperform | $15 | $4.98 | +201.20% | 1 | Oct 31, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $25 | $9.97 | +150.75% | 1 | Sep 17, 2025 | |
| CELC Celcuity | Maintains: Outperform | $28 → $60 | $115.24 | -47.93% | 2 | Jul 28, 2025 | |
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $13.72 | -34.40% | 6 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $6 | $5.53 | +8.50% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $880 → $762 | $764.93 | -0.38% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.16 | +944.30% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $145.14 | -33.86% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $97.33 | -19.86% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $15.22 | +83.97% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $197.52 | -60.00% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $2.19 | +1,135.70% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $15.60 | +60.26% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $5.70 | +601.75% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $3.03 | +2,111.22% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $17.95 | +11.42% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $16.83 | +48.54% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $10.33 | -22.56% | 7 | Jul 14, 2017 |
Zymeworks
Mar 3, 2026
Maintains: Outperform
Price Target: $52 → $58
Current: $24.80
Upside: +133.87%
Cogent Biosciences
Jun 13, 2022
Maintains: Outperform
Price Target: $14 → $15
Current: $37.46
Upside: -59.96%
Relmada Therapeutics
Jan 23, 2026
Upgrades: Outperform
Price Target: $8
Current: $4.43
Upside: +80.59%
Galecto
Jan 7, 2026
Initiates: Outperform
Price Target: $46
Current: $28.36
Upside: +62.20%
Agios Pharmaceuticals
Dec 26, 2025
Maintains: Outperform
Price Target: $34 → $40
Current: $27.68
Upside: +44.51%
Nuvalent
Nov 17, 2025
Maintains: Outperform
Price Target: $140 → $149
Current: $100.13
Upside: +48.81%
Immuneering
Oct 31, 2025
Initiates: Outperform
Price Target: $15
Current: $4.98
Upside: +201.20%
BridgeBio Oncology Therapeutics
Sep 17, 2025
Initiates: Outperform
Price Target: $25
Current: $9.97
Upside: +150.75%
Celcuity
Jul 28, 2025
Maintains: Outperform
Price Target: $28 → $60
Current: $115.24
Upside: -47.93%
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $13.72
Upside: -34.40%
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $5.53
Upside: +8.50%
Jan 28, 2025
Maintains: Market Perform
Price Target: $880 → $762
Current: $764.93
Upside: -0.38%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $3.16
Upside: +944.30%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $145.14
Upside: -33.86%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $97.33
Upside: -19.86%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $15.22
Upside: +83.97%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $197.52
Upside: -60.00%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $2.19
Upside: +1,135.70%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $15.60
Upside: +60.26%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $5.70
Upside: +601.75%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $3.03
Upside: +2,111.22%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $17.95
Upside: +11.42%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $16.83
Upside: +48.54%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $10.33
Upside: -22.56%